MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

Liposarcoma can be an aggressive, debilitating, and fatal malignancy. In this study, we identifed miRNAs associated with the differentiation status of liposarcoma to gain insight into the basis for its progression. miRNA expression profiles determined in human tumors and normal fat specimens identified a dedifferentiated tumor expression signature consisting of 35 miRNAs. Deregulated miRNA expression was confirmed in a second independent sample cohort. The miR-155 was the most overexpressed miRNA and functional investigations assigned an important role in the growth of dedifferentiated liposarcoma cell lines. Transient or stable knockdown of miR-155 retarded tumor cell growth, decreased colony formation, and induced G(1)-S cell-cycle arrest in vitro and blocked tumor growth in murine xenografts in vivo. We identified casein kinase 1α (CK1α) as a direct target of miR-155 control which enhanced β-catenin signaling and cyclin D1 expression, promoting tumor cell growth. In summary, our results point to important functions for miR-155 and β-catenin signaling in progression of liposarcoma, revealing mechanistic vulnerabilities that might be exploited for both prognostic and therapeutic purposes.

[1]  C. Sander,et al.  Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. , 2011, Cancer research.

[2]  S. Aaronson,et al.  High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. , 2011, Cancer cell.

[3]  W. Grizzle,et al.  miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT , 2011, Oncogene.

[4]  A. Lazar,et al.  An experimental model for the study of well differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors , 2010, Laboratory Investigation.

[5]  C. Croce,et al.  Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.

[6]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[7]  Shuai Jiang,et al.  MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. , 2010, Cancer research.

[8]  Domenico Coppola,et al.  MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer* , 2010, The Journal of Biological Chemistry.

[9]  Muller Fabbri,et al.  Modulation of mismatch repair and genomic stability by miR-155 , 2010, Proceedings of the National Academy of Sciences.

[10]  R. Nolo,et al.  Regulation of NOTCH Signaling by Reciprocal Inhibition of HES1 and Deltex 1 and its Role in Osteosarcoma Invasiveness , 2010, Oncogene.

[11]  H. Taubert,et al.  Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival , 2010, International journal of cancer.

[12]  T. Hupp,et al.  CK1α Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein Stability , 2009, The Journal of Biological Chemistry.

[13]  C. Croce,et al.  Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. , 2009, Blood.

[14]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[15]  M. Loda,et al.  c‐Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme , 2009, The Journal of pathology.

[16]  I. Faraoni,et al.  miR-155 gene: a typical multifunctional microRNA. , 2009, Biochimica et biophysica acta.

[17]  Wei-Lien Wang,et al.  Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome , 2009, Annals of surgery.

[18]  Quan-sheng Zhu,et al.  Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma , 2009, Clinical Cancer Research.

[19]  C. Langmead,et al.  ANGIOPOIETIN-2, A REGULATOR OF VASCULAR PERMEABILITY IN INFLAMMATION IS ELEVATED IN SEVERE ACUTE PANCREATITIS AND IS ASSOCIATED WITH SYSTEMIC ORGAN FAILURE , 2008 .

[20]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[21]  Domenico Coppola,et al.  MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA , 2008, Molecular and Cellular Biology.

[22]  S. Le,et al.  Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth , 2008, PloS one.

[23]  G. Tseng,et al.  MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.

[24]  T O Nielsen,et al.  MicroRNA expression signature of human sarcomas , 2008, Oncogene.

[25]  Aadel A. Chaudhuri,et al.  Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder , 2008, The Journal of experimental medicine.

[26]  Ladan Fazli,et al.  Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development , 2007, Proceedings of the National Academy of Sciences.

[27]  Margaret S. Ebert,et al.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.

[28]  T. Davison,et al.  MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma , 2007, Oncogene.

[29]  Molly Megraw,et al.  miRGen: a database for the study of animal microRNA genomic organization and function , 2006, Nucleic Acids Res..

[30]  C. Croce,et al.  CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control , 2006, Proceedings of the National Academy of Sciences.

[31]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[32]  J. Coindre,et al.  Retroperitoneal liposarcomas: Follow‐up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas , 2006, Cancer.

[33]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[34]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Stefano Volinia,et al.  Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Georgios Giamas,et al.  The Role of the Casein Kinase 1 (CK1) Family in Different Signaling Pathways Linked to Cancer Development , 2005, Oncology Research and Treatment.

[37]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[38]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[39]  Wayne Tam,et al.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  V. Ambros The functions of animal microRNAs , 2004, Nature.

[41]  M. Ballo,et al.  Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy , 2003, Cancer.

[42]  Samuel Singer,et al.  Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma , 2003, Annals of surgery.

[43]  Tsuyoshi Saito,et al.  β-Catenin Accumulation and Gene Mutation in Exon 3 in Dedifferentiated Liposarcoma and Malignant Fibrous Histiocytoma , 2002 .

[44]  Matthias Mann,et al.  Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. , 2002, Genes & development.

[45]  Axel Hoos,et al.  Analysis of the Prognostic Significance of Microscopic Margins in 2,084 Localized Primary Adult Soft Tissue Sarcomas , 2002, Annals of surgery.

[46]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[47]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[48]  F. Collin,et al.  Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors , 1999, Genes, chromosomes & cancer.

[49]  R. Mladick,et al.  Atypical lipoma, atypical intramuscular lipoma and well differentiated retroperitoneal liposarcoma , 1980 .

[50]  R. Winkelmann,et al.  Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma. A reappraisal of 30 cases formerly classified as well differentiated liposarcoma , 1979, Cancer.